Rhumbline Advisers boosted its position in BioTelemetry Inc (NASDAQ:BEAT) by 1.7% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 102,888 shares of the medical research company’s stock after purchasing an additional 1,687 shares during the quarter. Rhumbline Advisers’ holdings in BioTelemetry were worth $4,191,000 at the end of the most recent reporting period.
Other institutional investors have also recently made changes to their positions in the company. Arcadia Investment Management Corp MI bought a new position in BioTelemetry in the second quarter worth about $29,000. NumerixS Investment Technologies Inc bought a new position in BioTelemetry in the second quarter worth about $29,000. Capital Investment Advisory Services LLC bought a new position in BioTelemetry in the second quarter worth about $45,000. Tower Research Capital LLC TRC bought a new position in BioTelemetry in the second quarter worth about $50,000. Finally, Quantamental Technologies LLC bought a new position in BioTelemetry in the second quarter worth about $52,000. Institutional investors and hedge funds own 91.19% of the company’s stock.
In other news, SVP Peter Ferola sold 44,276 shares of the company’s stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $39.03, for a total transaction of $1,728,092.28. Following the transaction, the senior vice president now owns 19,622 shares in the company, valued at $765,846.66. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 6.50% of the company’s stock.
BioTelemetry (NASDAQ:BEAT) last posted its quarterly earnings data on Tuesday, November 5th. The medical research company reported $0.52 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.50 by $0.02. BioTelemetry had a net margin of 8.98% and a return on equity of 22.27%. The firm had revenue of $111.30 million for the quarter, compared to the consensus estimate of $111.19 million. During the same quarter in the prior year, the company posted $0.53 earnings per share. The company’s revenue for the quarter was up 11.3% compared to the same quarter last year. On average, research analysts anticipate that BioTelemetry Inc will post 1.97 EPS for the current fiscal year.
A number of brokerages have commented on BEAT. BidaskClub upgraded shares of BioTelemetry from a “sell” rating to a “hold” rating in a report on Saturday. Sidoti reduced their target price on shares of BioTelemetry from $95.00 to $87.00 and set a “buy” rating for the company in a report on Wednesday, July 31st. Zacks Investment Research downgraded shares of BioTelemetry from a “buy” rating to a “hold” rating in a report on Friday, August 2nd. ValuEngine upgraded shares of BioTelemetry from a “hold” rating to a “buy” rating in a report on Wednesday, October 2nd. Finally, Raymond James downgraded shares of BioTelemetry from an “outperform” rating to a “market perform” rating in a report on Friday, August 2nd. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $71.83.
BioTelemetry, Inc, a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core lab services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in Healthcare, Research, and Corporate and Other segments.
Further Reading: Investing in Dividend Stocks
Want to see what other hedge funds are holding BEAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioTelemetry Inc (NASDAQ:BEAT).
Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.